QR Pharma Inc., a Radnor company that is developing treatments for Alzheimer's disease, said Tuesday that it had received a $500,000 investment from BioAdvance and additional funding from angel investors.

It said those investments closed a one-year seed round totaling $2.4 million.

The money will be used to fund development of two compounds, Posiphen and Bisnorcymserine, to treat Alzheimer's disease and cognitive impairment.    - Stacey Burling